Multisystem Inflammatory Syndrome Associated with COVID-19 Anti-thrombosis Guideline of Care for Children by Action.
Neha BansalEstela AzekaCindy NeunertJohn S KimJenna MurrayLindsay MayChrista KirkAngela LortsDavid RosenthalChristina VanderPluymPublished in: Pediatric cardiology (2021)
With growing number of pediatric cases of COVID-19, a unique hyper-inflammatory syndrome, linked to SARS-CoV-2 infection, has emerged in children referred to as multisystem inflammatory syndrome in children (MIS-C). This Kawasaki Disease (KD)-like illness has been described across the world. This syndrome shares features of KD, toxic shock syndrome, and macrophage activation syndrome and is associated with significantly elevated inflammatory markers. Everyday there are new data emerging improving the care of these patients. The Advanced Cardiac Therapies Improving Outcomes Network (ACTION) is a collaborative network designed to improve the outcomes of pediatric patients with end-stage heart failure and involves centers from across North America. The committee gathered information concerning COVID-19 anticoagulation practices at various centers and harmonized the data to formulate a set of recommendations.
Keyphrases
- coronavirus disease
- healthcare
- heart failure
- sars cov
- case report
- young adults
- oxidative stress
- palliative care
- quality improvement
- primary care
- atrial fibrillation
- ejection fraction
- type diabetes
- newly diagnosed
- metabolic syndrome
- machine learning
- venous thromboembolism
- respiratory syndrome coronavirus
- deep learning
- weight loss
- prognostic factors
- chronic pain
- patient reported
- affordable care act